The biomechanical model of heart failure is the accepted model that can explain the progressive nature of the disease. Left ventricle (LV) remodelling is the main cause of heart failure secondary to myocardial infarction (MI). The three major biomechanical mechanisms of remodelling after MI are; infarct expansion, non-ischemic infarct extension and eccentric hypertrophy of non-infarcted myocardium. We reviewed mechanisms of post MI remodelling, current and potential therapies.

Keywords:remodelling, post infarction, mechanisms.

1.      Cohn JN. Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition. Circulation (1995); 91(10):2504–07.

2.      Tiyyagura SR and Pinney SP. Left ventricular remodeling after myocardial infarction: past, present, and future. Mount Sinai Journal of Medicine (2006); 73(6):840–51.

3.      Eghbali M, Blumenfeld OO and Seifter S. et al. Localisation of types I, III, and IV collagen mRNAs in rat heart cells by in situ hybridization. Journal of Molecular and Cellular Cardiology (1989); 21:103–13.

4.      Eghbali M, Tomek R and Woods C. et al. Cardiac fibroblasts are predisposed to convert into myocyte phenotype: specific effect of transforming growth factor α. Proceedings of the National Academy of Sciences. USA (1991); 88:795–99.

5.      Weber KT. Extracellular matrix remodelling in heart failure: a role for de novo angiotensin II generation. Circulation (1997); 96:4065– 82.

6.      Erlebacher JA, Weiss JL and Weisfeldt ML. et al. Early dilation of the infarcted segment in acute transmural myocardial infarction: role of infarct expansion in acute left ventricular enlargement. Journal of the American College of Cardiology (1984); 4:201–08.

7.      Zak R. Development and proliferative capacity of cardiac muscle cells. Circulation Research (1974); 35(II):17–26.

8.      Alberts B, Bray D and Lewis J. et al. Molecular Biology of the Cell. 3^rd ed. New York, NY (1994). Garland Publishing.

9.      Feigenbaum, Harvey and Armstrong et al. Echocardiographic evaluation of clinical syndromes. Coronary Artery Disease. Feigenbaum's Echocardiography (2005); 6^th Ed; Chapter 15: 451- 61.

10.  Cleutjens JP, Kandala JC and Guarda E. et al. Regulation of collagen degradation in the rat myocardium after infarction. Journal of Molecular and Cellular Cardiology (1995); 27:1281–92.

11.  Brent A. French and Christopher M. Kramer. Mechanisms of Post-Infarct Left Ventricular Remodelling. Drug Discovery Today Disease Mechanisms (2007); 4(3): 185–96.

12.  Ratcliffe MB. Non-ischemic infarct extension: A new type of infarct enlargement and a potential therapeutic target. Journal of the American College of Cardiology (2002); 40:1168–71.

13.  Kelley ST. et al. Restraining infarct expansion preserves left ventricular geometry and function after acute anteroapical infarction. Circulation (1999); 99(1):135–42.

14.  Jackson BM. et al. Extension of border zone myocardium in postinfarction dilated cardiomyopathy. Journal of the American College of Cardiology (2002); 40(6):1160–67.

15.  Cheng A. et al. Passive ventricular constraint prevents transmural shear strain progression in left ventricle remodelling. Circulation (2006); 114(1 Suppl):I79–I86.

16.  Feigenbaum, Harvey and Armstrong et al. Feigenbaum's Echocardiography (2005). Coronary Artery Disease, Clinical overview, 6^th ed. Chapter 15- 438-42.

17.  Hutchins GM and Bulkley BH. Infarct expansion versus extension: Two different complications of acute myocardial infarction. American Journal of Cardiology (1978); 41:1127-32.

18.  Olivetti G, Capasso JM and Sonnenblick EH. et al. Side-to-side slippage of myocytes participates in ventricular wall remodelling acutely after myocardial infarction in rats. Circulation Research (1990); 67:23–34

19.  Factor SM, Flomenbaum M and Zhao MJ. et al. The effects of acutely increased ventricular cavity pressure on intrinsic myocardial connective tissue. Journal of the American College of Cardiology (1988); 12:1582-89

20.  Giorgio Olivetti, Joseph M. Capasso and Edmund H. Sonnenblick et al. Side-to-Side Slippage of Myocytes Participates in Ventricular Wall Remodelling Acutely After Myocardial Infarction in Rats. Circulation Research (1990); 67:23-34.

21.  Woessner JF Jr. The matrix metalloproteinase family. In: Parks WC, Mecham RP, eds. Matrix Metalloproteinases. San Diego, Calif: Academic Press (1998); 1–14.

22.  Jeffrey JJ. Collagen degradation. In: Cohen IK, Diegelmann RF, Lindblad WJ, eds. Wound Healing: Biochemical and Clinical Aspects. Philadelphia, Pa: WB Saunders Co (1992); 177–94.

23.  Weaver WD, Simes RJ and Betriu A. et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. Journal of the American Medical Association (1997); 278:2093–98.

24.  Hideki Ishii, Tetsuya Amano and Tatsuaki Matsubara et al. Pharmacological Intervention for Prevention of Left Ventricular Remodelling and Improving Prognosis in Myocardial Infarction. Circulation (2008); 118:2710-18.

25.  Bruce R. Brodie, Thomas D. Stuckey and Grace Kissling et al. Importance of Infarct-Related Artery Patency for Recovery of Left Ventricular Function and Late Survival after Primary Angioplasty for Acute Myocardial Infarction. Journal of American College of Cardiology (1996); 28:319-25.

26.  Henry Shih, Brian Lee and Randall J. Lee et al. The Aging Heart and Post-Infarction Left Ventricular Remodelling. American College of Cardiology (2010); 28; 57(1): 9–17.

27.  Pfeffer MA and Braunwald E. Ventricular remodelling after myocardial infarction. Experimental observations and clinical implications. Circulation (1990); 81:1161–72.

28.  Zornoff LAM, Matsubara BB and Matsubara LS. et al. Cigarette smoke exposure intensifies ventricular remodelling process following myocardial infarction. Arquivos Brasileiros de Cardiologia (2006); 86: 276-82.

29.  Nicolau JC, Maia LN and Vitola J. et al. Baseline glucose and left ventricular remodelling after acute myocardial infarction. Journal of Diabetes Complications (2007); 21: 294-9.

30.  Lobna F. Eltony, Salah A Argoon, Ahmad B. Elden. Impact of Admission Hyperglycemia on Postmyocardial Infarction Left Ventricular Remodelling.Journal of medical science and clinical research (2014); 2: 07.

31.  Solomon SD, Anavekar NS and Greaves S. et al. Angina pectoris prior to myocardial infarction protects against subsequent left ventricular remodelling. Journal of American College of Cardiology (2004); 43:1511–14.

32.  Kitakaze M, Minamoto T and Node K. et al. Role of activation of ectosolic 5-nucleotidase in the cardioprotection mediated by opening of K⁺ c channels. American Journal of Physiology, Heart and Circulation Physiology (1996); 270:H1744–H56.

33.  Oldenburg O, Cohen MV and Yellon DM. et al. Mitochondrial K_ATP channels: role in ischaemic preconditioning. Cardiovasc-ular Research (2002); 55: 429–37.

34.  Hausenloy DJ, Tsang A and Yellon DM. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and post conditioning. Trends Cardiovascular Medicine (2005); 15:69 –75.

35.  Bell RM and Yellon DM. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. Journal of American College of Cardiology (2003); 41:508–15.

36.  Higuma T, Matsunaga T and Maeda N. et al. Early statin treatment before coronary intervention protects against reperfusion injury and reduces infarct size in patients with acute myocardial infarction. Circulation (2005); 112 (l): II-569. Abstract.

37.  Hayashi M, Tsutamoto T and Wada A. et al. Relationship between transcardiac extraction of aldosterone and left ventricular remodelling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodelling after acute myocardial infarction. Journal of American College of Cardiology (2001); 38:1375–82.

38.  Jugdutt BI. Remodeling of the myocardium and potential targets in the collagen degradation and synthesis pathways. Current Drug Targets Cardiovascular and Hematology Disorders (2003); 3:1–30.

39.  Malhotra R. et al. Mechanical stretch and angiotensin II differentially up regulate the renin-angiotensin system in cardiac myocytes in vitro. Circulation Research (1999); 85(2):137–46.

40.  Akasaka Y. et al. Myocardial apoptosis associated with the expression of proinflammatory cytokines during the course of myocardial infarction. Modern Pathology (2006); 19(4):588–98.

41.  Gilson WD. et al. Border zone contractile dysfunction is transiently attenuated and left ventricular structural remodelling is markedly reduced following reperfused myocardial infarction in inducible nitric oxide synthase knockout mice. Journal of the American College of Cardiology (2007); 50(18): 1799–1807.

42.  Valentin Fuster, Richard A. Walsh and Robert A. O'Rourke et al. Hurst's the Heart (2009); 12^th ed. e Chapter 24.

43.  Douglas L. Mann. Pathophysiology of Heart Failure. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine (2007); 8^th ed. Chapter 22: 541-60.

44.  Sadanandan S, Buller C and Menon V. et al. The late open artery hypothesis—a decade later.  American Heart Journal (2001); 142:411.

45.  Molkentin JD, Lu J-R and Antos CL. et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell (1998); 93:215–28.

46.  Frey N and Olson EN. Cardiac hypertrophy: the good, the bad and the ugly. Annul Revision of Physiology (2003); 65:45–79.

47.  Ventura HO, Malik FS and Mehra MR. et al. Mechanisms of hypertension in cardiac transplantation and the role of cyclosporine. Current Opinion in Cardiology (1997); 12:375–81.

48.  Olson EN and Williams RS. Calcineurin signaling and muscle remodeling. Cell (2000); 101:689–92.

49.  Clerk A. and Sugden PH. Small guanine nucleotide-binding proteins and myocardial hypertrophy. Circulation Research (2000); 86:1019–23.

50.  Hunter JJ, Tanaka N and Rockman HA. et al. Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. Journal of Biological Chemistry (1995); 270:23173–178.

51.  Hoshijima M, Sah VP and Wang YB. et al. The low molecular weight GTPase rho regulates myofibril formation and organization in neonatal rat ventricular myocytes: involvement of Rho kinase. Journal of Biological Chemistry (1998); 273:7725–30.

52.  Charron F, Tsimiklis G and Areand M. et al. Tissue-specific GATA factors are transcriptional effectors of the small GTPase RhoA. Genes and Development (2001); 15:2702–19.

53.  Oi S, Haneda T and Osaki J. et al. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. European Journal of Pharmacology (1999); 376:139–48.

54.  Luo JD, Xie F and Zhang WW. et al. Simvastatin inhibits noradrenaline induced hypertrophy of cultured neonatal rat cardiomyocytes. British Journal of Pharmacology (2001); 132:159–64.

55.  Luo JD, Zhang WW and Zhang GP. et al. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clinical and Experimental Pharmacology and Physiology (1999); 26:903–08.

56.  Hayashidani S, Tsutsui H and Shiomi T. et al. Fluvastatin, a 3-hydroxy-3- methylglut-aryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation (2002);105:868–73.

Ahmad B. Elden

MD, Internal Medicine Department, Critical Care Unite,

Assiut University, P.O. Box 71111 Assiut, Egypt

Email: This email address is being protected from spambots. You need JavaScript enabled to view it. Telephone: +20-1009820300 Fax: +20-2333327